Market Cap
€15.1b
Last Updated
2021/01/20 18:38 UTC
Data Sources
Company Financials +
Executive Summary
Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. More Details
Snowflake Analysis
Solid track record with mediocre balance sheet.
Similar Companies
Share Price & News
How has Grifols's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GRF is not significantly more volatile than the rest of Spanish stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: GRF's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
5.0%
GRF
5.2%
ES Biotechs
-1.6%
ES Market
1 Year Return
-19.7%
GRF
11.4%
ES Biotechs
-11.5%
ES Market
Return vs Industry: GRF underperformed the Spanish Biotechs industry which returned 11.4% over the past year.
Return vs Market: GRF underperformed the Spanish Market which returned -11.5% over the past year.
Shareholder returns
| GRF | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.0% | 5.2% | -1.6% |
| 30 Day | 4.9% | 7.7% | 5.0% |
| 90 Day | 2.3% | 10.4% | 18.2% |
| 1 Year | -19.2%-19.7% | 12.0%11.4% | -9.0%-11.5% |
| 3 Year | -1.3%-4.1% | 35.0%32.7% | -9.4%-18.1% |
| 5 Year | 39.0%31.9% | 72.8%66.9% | 14.5%-2.9% |
Long-Term Price Volatility Vs. Market
How volatile is Grifols's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Grifols (BME:GRF) Has A Somewhat Strained Balance Sheet1 month ago | Simply Wall St
What To Know Before Buying Grifols, S.A. (BME:GRF) For Its Dividend1 month ago | Simply Wall St
What Kind Of Shareholders Own Grifols, S.A. (BME:GRF)?Valuation
Is Grifols undervalued compared to its fair value and its price relative to the market?
25.32x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GRF (€25.37) is trading above our estimate of fair value (€18.46)
Significantly Below Fair Value: GRF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GRF is good value based on its PE Ratio (25.3x) compared to the XE Biotechs industry average (44.5x).
PE vs Market: GRF is poor value based on its PE Ratio (25.3x) compared to the Spanish market (21.4x).
Price to Earnings Growth Ratio
PEG Ratio: GRF is poor value based on its PEG Ratio (1.7x)
Price to Book Ratio
PB vs Industry: GRF is good value based on its PB Ratio (3.3x) compared to the XE Biotechs industry average (5.5x).
Next Steps
Future Growth
How is Grifols forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
14.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GRF's forecast earnings growth (14.6% per year) is above the savings rate (1.1%).
Earnings vs Market: GRF's earnings (14.6% per year) are forecast to grow slower than the Spanish market (33.9% per year).
High Growth Earnings: GRF's earnings are forecast to grow, but not significantly.
Revenue vs Market: GRF's revenue (5.6% per year) is forecast to grow slower than the Spanish market (6.1% per year).
High Growth Revenue: GRF's revenue (5.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GRF's Return on Equity is forecast to be low in 3 years time (14.9%).
Next Steps
Past Performance
How has Grifols performed over the past 5 years?
3.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GRF has high quality earnings.
Growing Profit Margin: GRF's current net profit margins (12.7%) are higher than last year (11.1%).
Past Earnings Growth Analysis
Earnings Trend: GRF's earnings have grown by 3.8% per year over the past 5 years.
Accelerating Growth: GRF's earnings growth over the past year (24.4%) exceeds its 5-year average (3.8% per year).
Earnings vs Industry: GRF earnings growth over the past year (24.4%) exceeded the Biotechs industry 7.3%.
Return on Equity
High ROE: GRF's Return on Equity (10.5%) is considered low.
Next Steps
Financial Health
How is Grifols's financial position?
Financial Position Analysis
Short Term Liabilities: GRF's short term assets (€3.6B) exceed its short term liabilities (€1.2B).
Long Term Liabilities: GRF's short term assets (€3.6B) do not cover its long term liabilities (€7.3B).
Debt to Equity History and Analysis
Debt Level: GRF's debt to equity ratio (88.7%) is considered high.
Reducing Debt: GRF's debt to equity ratio has reduced from 142.4% to 88.7% over the past 5 years.
Debt Coverage: GRF's debt is not well covered by operating cash flow (17.1%).
Interest Coverage: GRF's interest payments on its debt are well covered by EBIT (13x coverage).
Balance Sheet
Next Steps
Dividend
What is Grifols's current dividend yield, its reliability and sustainability?
1.36%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GRF's dividend (1.36%) isn’t notable compared to the bottom 25% of dividend payers in the Spanish market (2.17%).
High Dividend: GRF's dividend (1.36%) is low compared to the top 25% of dividend payers in the Spanish market (6.85%).
Stability and Growth of Payments
Stable Dividend: GRF's dividend payments have been volatile in the past 10 years.
Growing Dividend: GRF's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (14.5%), GRF's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GRF's dividends in 3 years are forecast to be well covered by earnings (37.4% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
13.0yrs
Average management tenure
CEO
Raimon Grifols Roura (56 yo)
4yrs
Tenure
Mr. Raimon Grifols Roura has been the Co-Chief Executive Officer of Grifols, S.A. since January 1, 2017 and served as its Co-Chairman. Mr. Roura was a Patner at Osborne Clarke Spain. Mr. Roura serves as th...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-CEO & Executive Director | 4yrs | no data | 0.00041% € 62.1k | |
| Vice Secretary & External Director | 20.75yrs | no data | 0.015% € 2.3m | |
| Co-CEO & Executive Director | 4.67yrs | no data | 0.0021% € 324.1k | |
| CFO & VP | 14yrs | no data | no data | |
| Corporate Vice President and Director of Scientific & Medical Affairs | 14yrs | no data | no data | |
| Vice President of Corporate Treasury & Investor Relations | no data | no data | 0.0029% € 433.1k | |
| General Counsel & Chief Innovation Officer | 18yrs | no data | 0.0029% € 442.2k | |
| Vice President of Corporate Communications | 3yrs | no data | 0.00010% € 15.1k | |
| Corporate VP & Chief Human Resources Officer | 13yrs | no data | 0.00014% € 21.2k | |
| Corporate Vice President and President of the Biological Industrial Group | 26yrs | no data | no data | |
| Corporate Vice President and Director of Corporate Accounting & Reporting | 30yrs | no data | no data | |
| President of the Bio Supplies Division | 3yrs | no data | 0.0039% € 596.6k |
13.0yrs
Average Tenure
61yo
Average Age
Experienced Management: GRF's management team is seasoned and experienced (13 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-CEO & Executive Director | 4yrs | no data | 0.00041% € 62.1k | |
| Vice Secretary & External Director | 20.75yrs | no data | 0.015% € 2.3m | |
| Co-CEO & Executive Director | 4.67yrs | no data | 0.0021% € 324.1k | |
| Independent Director | 10yrs | €125.00k | no data | |
| Independent Non-Executive Vice-Chairman | 4yrs | €845.00k | 0.0054% € 820.7k | |
| Non-Executive Chairman | 18.67yrs | €1.24m | 0.13% € 19.5m | |
| Member of the Advisory Committee | 6yrs | €380.00k | no data | |
| Independent Other External Director | 20.75yrs | €913.00k | 0.049% € 7.5m | |
| Independent Director | 7.67yrs | €150.00k | no data | |
| Independent Director | 6.67yrs | €125.00k | no data | |
| Lead Independent Director | 4yrs | €75.00k | no data | |
| Independent Director | 5.67yrs | €63.00k | 0.00022% € 33.3k |
6.3yrs
Average Tenure
61yo
Average Age
Experienced Board: GRF's board of directors are considered experienced (6.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Grifols, S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Grifols, S.A.
- Ticker: GRF
- Exchange: BME
- Founded: 1940
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €15.143b
- Shares outstanding: 684.54m
- Website: https://www.grifols.com
Number of Employees
Location
- Grifols, S.A.
- Avinguda de la Generalitat, 152
- Parc empresarial Can Sant Joan
- Barcelona
- Catalonia
- 8174
- Spain
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GRF | BME (Bolsas y Mercados Espanoles) | Yes | Class A Shares | ES | EUR | May 2006 |
| OZTA | DB (Deutsche Boerse AG) | Yes | Class A Shares | DE | EUR | May 2006 |
| 0RDU | LSE (London Stock Exchange) | Yes | Class A Shares | GB | EUR | May 2006 |
| GIFL.F | OTCPK (Pink Sheets LLC) | Yes | Class A Shares | US | USD | May 2006 |
| GRFE | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Class A Shares | GB | EUR | May 2006 |
| GRF | WBAG (Wiener Boerse AG) | Yes | Class A Shares | AT | EUR | May 2006 |
| OZTA | ETLX (Eurotlx) | Yes | Class A Shares | IT | EUR | May 2006 |
| GIKL.Y | OTCPK (Pink Sheets LLC) | SPONS ADR | US | USD | Jul 2009 | |
| GRFS | NasdaqGS (Nasdaq Global Select) | SP ADR REP B NVT | US | USD | Jun 2011 | |
| GRF.P | BME (Bolsas y Mercados Espanoles) | Class B Non-Voting Shares | ES | EUR | Jun 2011 | |
| 0RDV | LSE (London Stock Exchange) | Class B Non-Voting Shares | GB | EUR | Jun 2011 | |
| G0FB | DB (Deutsche Boerse AG) | SP ADR REP B NVT | DE | EUR | Jun 2011 | |
| GRFPE | BATS-CHIXE (BATS 'Chi-X Europe') | Class B Non-Voting Shares | GB | EUR | Jun 2011 | |
| GIFO.F | OTCPK (Pink Sheets LLC) | Class B Non-Voting Shares | US | USD | Jun 2011 | |
| GRFP N | BMV (Bolsa Mexicana de Valores) | Class B Non-Voting Shares | MX | MXN | Jun 2011 |
Biography
Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supp...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/20 18:38 |
| End of Day Share Price | 2021/01/20 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.